Stockscreener 앱 받기
4.54
4.85%
0.21
Silence Therapeutics Plc Adr 주식(SLN)의 최신 뉴스
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1%Here's What Happened - MarketBeat
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - Sahm
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 - Investing.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7%Should You Sell? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell? - Defense World
Silence Therapeutics Insider Ups Holding During Year - Sahm
Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & Silence Therapeutics (NASDAQ:SLN) - Defense World
Was Autonomix Medical Inc (AMIX)’s session last reading good? - uspostnews.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors By Investing.com - Investing.com South Africa
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com
Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Falcon’s Beyond Global Inc (FBYD) expanding its growth trajectory ahead - setenews.com
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com South Africa
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics (SLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - Yahoo Finance
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Nasdaq
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics director Alistair Gray retires - Investing.com
Zerlasiran shows promise in lowering cardiovascular risk - Investing.com
1.24%
0.19%
자본화:
|
볼륨(24시간):